- Home
- TRIN vs OCS Comparison
TRIN vs OCS Comparison
Compare TRIN & OCS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | TRIN | OCS |
|---|---|---|
| Founded | 2007 | 2003 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 1.0B |
| IPO Year | 2021 | N/A |
Fundamental Metrics
Financial Performance| Metric | TRIN | OCS |
|---|---|---|
| Price | $15.09 | $20.67 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 5 | 5 |
| Target Price | $16.00 | ★ $39.80 |
| AVG Volume (30 Days) | ★ 722.2K | 97.6K |
| Earning Date | 11-05-2025 | 11-10-2025 |
| Dividend Yield | ★ 13.44% | N/A |
| EPS Growth | ★ 25.79 | N/A |
| EPS | ★ 2.17 | N/A |
| Revenue | ★ $268,271,000.00 | $991,999.00 |
| Revenue This Year | $29.07 | $35.00 |
| Revenue Next Year | $13.52 | $874.12 |
| P/E Ratio | $7.01 | ★ N/A |
| Revenue Growth | ★ 30.76 | N/A |
| 52 Week Low | $12.50 | $14.00 |
| 52 Week High | $16.82 | $23.08 |
Technical Indicators
Market Signals| Indicator | TRIN | OCS |
|---|---|---|
| Relative Strength Index (RSI) | 55.95 | 57.99 |
| Support Level | $14.47 | $18.64 |
| Resistance Level | $15.35 | $21.86 |
| Average True Range (ATR) | 0.22 | 0.63 |
| MACD | 0.07 | 0.15 |
| Stochastic Oscillator | 72.32 | 62.42 |
Price Performance
Historical ComparisonAbout TRIN Trinity Capital Inc.
Trinity Capital Inc is a closed-end, non-diversified management investment company. The company is engaged in providing debt, including loans and equipment financings, to growth-stage companies, including venture-backed companies and companies with institutional equity investors. Its equipment financings involve loans for general or specific use, including acquiring equipment, secured by the equipment or other assets of the portfolio company.
About OCS Oculis Holding AG Ordinary shares
Oculis Holding AG is a global biopharmaceutical company purposefully driven to save sight and improve eye care. It includes OCS-01, a topical retinal candidate for diabetic macular edema (DME); OCS-02, a topical biologic candidate for dry eye disease (DED); and OCS-05, a disease modifying candidate for acute optic neuritis (AON) and other neuro-ophtha disorders such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis.